利巴韦林治疗小儿病毒性感染合并白细胞减少症的临床分析

The Clinical Analysis of Ribavirin Used in Nature of Virus Tract Infection in Pediatric Patients with Infective Leukocytopenia

目的探讨临床应用利巴韦林治疗小儿病毒性感染合并白细胞减少症是否安全可行。方法将86例病毒性感染合并白细胞减少症的小儿,分别用利巴韦林、其他抗病毒药物进行随机分组治疗,从两组患儿在用药后外周血白细胞升至正常的时间、利巴韦林组是否出现白细胞进行性减少、两组病人抗病毒药物费用等方面进行探讨分析。结果发现正常剂量的利巴韦林在治疗小儿病毒性感染合并白细胞减少症疗效确切,没有出现其本身可能导致白细胞减少的副作用,与其他抗病毒药物比较临床疗效无差异性,并且价格低廉,可减轻患儿经济负担。结论治疗小儿病毒性感染合并白细胞减少症可以选用利巴韦利。

Objective the article investigated the clinical application value and security of Ribavirin in nature of virus tract infection in pediatric patients with infective leukocytopenia . Methods 86 cases of nature of virus tract infection with infective leukocytopenia were divided into Ribavirin group （46 patients） and other antiviral drug group （40 patients） . we compared the two groups regarding to success rate , time for peripheral leukocytes recovering and charges for antiviral drug . Results we did not find difference in success rate and time for peripheral leukocytes recovering between two groups . Ribavirin group need less charges than other antiviral drug group . Conclusion Ribavirin is a safe , availability , and cheap antiviral drug which can be used widely in nature of virus tract infection in pediatric patients with infective leukocytopenia.